Aventis DTaP Concurrent Use Data Should Precede Approval, Committee Says
• By The Pink Sheet
Approval for Aventis' five-component DTaP vaccine should await submission of safety and immunogenicity data with respect to its use in combination with other childhood vaccines, FDA's Vaccines & Related Biological Products Advisory Committee said Nov. 3.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
